[Results of clinical study of the antineoplastic antibiotic rubomycin].
D000293:Adolescent; D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy; D001943:Breast Neoplasms / Q000188:drug therapy; D004938:Esophageal Neoplasms / Q000188:drug therapy; D005260:Female; D005354:Fibrosarcoma / Q000188:drug therapy; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy; D006689:Hodgkin Disease / Q000188:drug therapy; D006801:Humans; D008080:Liposarcoma / Q000188:drug therapy; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy; D008297:Male; D008545:Melanoma / Q000188:drug therapy; D008875:Middle Aged; D009062:Mouth Neoplasms / Q000188:drug therapy; D009362:Neoplasm Metastasis / Q000188:drug therapy; D009369:Neoplasms / Q000188:drug therapy*; D012142:Respiratory Tract Neoplasms / Q000188:drug therapy; D012878:Skin Neoplasms / Q000188:drug therapy; D014067:Tonsillar Neoplasms / Q000188:drug therapy; D014594:Uterine Neoplasms / Q000188:drug therapy
D000903:Antibiotics, Antineoplastic
Rezul'taty klinicheskogo izucheniia protivoopukholevogo antibiotika rubomitsina.